pMD-Membrane: A Method for Ligand Binding Site Identification in Membrane-Bound Proteins

PLoS Computational Biology

Volumn 11, Issue 10, 2015, Pages

  Prakash, Priyanka ^a   Sayyed Ahmad, Abdallah ^a   Gorfe, Alemayehu A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING SITES; LIGANDS; MOLECULAR DYNAMICS; MOLECULES; PROBES; PROTEINS;

DRUG TARGETS; DYNAMICS SIMULATION; LIGAND-BINDING SITES; MEMBRANE-BOUND PROTEINS; MIXED SOLVENT; PROBE MOLECULES; PROBE-BASED; SITE IDENTIFICATION; SOLUBLE PROTEINS; SOLVENT MOLECULAR;

LIPID BILAYERS;

BINDING PROTEIN; K RAS PROTEIN; LIPID BILAYER; PROTEIN BINDING; RAS PROTEIN;

ALLOSTERISM; ANALYTIC METHOD; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; LIGAND BINDING; LIPID BILAYER; MEMBRANE BINDING; MOLECULAR DYNAMICS; MOLECULAR PROBE; MUTATIONAL ANALYSIS; PROBE BASED MOLECULAR DYNAMICS MEMBRANE; PROTEIN BINDING; ALGORITHM; CELL MEMBRANE; CHEMICAL MODEL; CHEMISTRY; PROCEDURES; PROTEIN ANALYSIS; PROTEIN CONFORMATION; SOFTWARE; ULTRASTRUCTURE;

ALGORITHMS; BINDING SITES; CELL MEMBRANE; LIPID BILAYERS; MODELS, CHEMICAL; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION MAPPING; RAS PROTEINS; SOFTWARE;

EID: 84946030094     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004469     Document Type: Article

References (74)

1. Perot S, Sperandio O, Miteva MA, Camproux AC, Villoutreix BO, Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. Drug Discov Today 2010;15: 656–667. doi: 10.1016/j.drudis.2010.05.015 20685398
2. Lu S, Huang W, Zhang J, Recent computational advances in the identification of allosteric sites in proteins. Drug Discov Today 2014;19:1595–1600. doi: 10.1016/j.drudis.2014.07.012 25107670
3. Allen KN, Bellamacina CR, Ding X, Jeffery CJ, Mattos C, Petsko GA, Ringe D, An Experimental Approach to Mapping the Binding Surfaces of Crystalline Proteins. J Phys Chem 1996;100: 2605–2611.
4. Dennis S, Kortvelyesi T, Vajda S, Computational mapping identifies the binding sites of organic solvents on proteins. Proc Natl Acad Sci U S A 2002;99: 4290–4295. 11904374
5. Hajduk PJ, Huth JR, Fesik SW, Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 2005;48: 2518–2525. 15801841
6. Durrant JD, McCammon JA, Molecular dynamics simulations and drug discovery. BMC Biol 2011;9: 71. doi: 10.1186/1741-7007-9-71 22035460
7. Seco J, Luque FJ, Barril X, Binding site detection and druggability index from first principles. J Med Chem 2009;52: 2363–2371. doi: 10.1021/jm801385d 19296650
8. Bakan A, Nevins N, Lakdawala AS, Bahar I, Druggability Assessment of Allosteric Proteins by Dynamics Simulations in the Presence of Probe Molecules. J Chem Theory Comput 2012;8: 2435–2447. 22798729
9. Guvench O, MacKerell AD, JrComputational Fragment-Based Binding Site Identification by Ligand Competitive Saturation. PLoS Comput Biol 2009;5: e1000435. doi: 10.1371/journal.pcbi.1000435 19593374
10. Huang D, Caflisch A, Small molecule binding to proteins: affinity and binding/unbinding dynamics from atomistic simulations. ChemMedChem 2011;6: 1578–1580. doi: 10.1002/cmdc.201100237 21674810
11. Prakash P, Hancock JF, Gorfe AA, Binding hotspots on K-ras: Consensus ligand binding sites and other reactive regions from probe-based molecular dynamics analysis. Proteins 2015;83: 898–909. doi: 10.1002/prot.24786 25740554
12. Lexa KW, Carlson HA, Full protein flexibility is essential for proper hot-spot mapping. J Am Chem Soc 2011;133: 200–202. doi: 10.1021/ja1079332 21158470
13. Raman EP, Yu W, Guvench O, MacKerell AD, Reproducing Crystal Binding Modes of Ligand Functional Groups Using Site-Identification by Ligand Competitive Saturation (SILCS) Simulations. J Chem Inf Model 2011;51: 877–896. doi: 10.1021/ci100462t 21456594
14. Gorfe AA, Mechanisms of allostery and membrane attachment in Ras GTPases: implications for anti-cancer drug discovery. Curr Med Chem 2010;17: 1–9. 19941482
15. Lundstrom K, Latest development in drug discovery on G protein-coupled receptors. Curr Protein Pept Sci 2006;7: 465–470. 17073697
16. Prakash P, Gorfe AA, Overview of simulation studies on the enzymatic activity and conformational dynamics of the GTPase Ras. Mol Simul 2014;40: 839–847.
17. Prakash P, Gorfe AA, Lessons from computer simulations of Ras proteins in solution and in membrane. Biochim Biophys Acta 2013;1830: 5211–5218. doi: 10.1016/j.bbagen.2013.07.024 23906604
18. Tautermann CS, Seeliger D, Kriegl JM, What can we learn from molecular dynamics simulations for GPCR drug design? Comput Struct Biotechnol J 2015;13: 111–121. doi: 10.1016/j.csbj.2014.12.002 25709761
19. Lappano R, Maggiolini M, G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011;10: 47–60. doi: 10.1038/nrd3320 21193867
20. Prakash P, Gorfe AA, Phosphatidylcholine attenuates aggregation of nonsteroidal anti-inflammatory drugs with bile acid. Biochemistry 2013;52: 7461–7469. doi: 10.1021/bi400723r 24066846
21. Prakash P, Sayyed-Ahmad A, Zhou Y, Volk DE, Gorenstein DG, Dial E, Lichtenberger LM, Gorfe AA, Aggregation behavior of ibuprofen, cholic acid and dodecylphosphocholine micelles. Biochim Biophys Acta 2012; 1818: 3040–3047. doi: 10.1016/j.bbamem.2012.07.029 22885171
22. Sayyed-Ahmad A, Lichtenberger LM, Gorfe AA, Structure and Dynamics of Cholic Acid and Dodecylphosphocholine—Cholic Acid Aggregates. Langmuir 2010;26: 13407–13414. doi: 10.1021/la102106t 20695585
23. Boggara MB, Krishnamoorti R, Partitioning of nonsteroidal antiinflammatory drugs in lipid membranes: a molecular dynamics simulation study. Biophys J 2010;98: 586–595. doi: 10.1016/j.bpj.2009.10.046 20159155
24. Soares ARM, Thanaiah Y, Taniguchi M, Lindsey JS, Aqueous-membrane partitioning of [small beta]-substituted porphyrins encompassing diverse polarity. New J Chem 2013;37: 1087–1097.
25. Cox AD, Der CJ, Ras history: The saga continues. Small GTPases 2010;1: 2–27. 21686117
26. Barbacid M, Ras Genes. Annu Rev Biochem 1987;56: 779–827. 3304147
27. Karnoub AE, Weinberg RA, Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008; 9: 517–531. doi: 10.1038/nrm2438 18568040
28. Bos JL, Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682–4689. 2547513
29. Prior IA, Lewis PD, Mattos C, A comprehensive survey of Ras mutations in cancer. Cancer Res 2012;72: 2457–2467. doi: 10.1158/0008-5472.CAN-11-2612 22589270
30. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ, Drugging the undruggable RAS: Mission Possible? Nat Rev Drug Discov 2014;13: 828–851. doi: 10.1038/nrd4389 25323927
31. Wang W, Fang G, Rudolph J, Ras inhibition via direct Ras binding—is there a path forward? Bioorg Med Chem Lett 2012;22: 5766–5776. doi: 10.1016/j.bmcl.2012.07.082 22902659
32. Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, Skelton NJ, Fauber BP, Pan B, Malek S, Stokoe D, Ludlam MJ, Bowman KK, Wu J, Giannetti AM, Starovasnik MA, Mellman I, Jackson PK, Rudolph J, Wang W, Fang G, Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A 2012;109: 5299–5304. doi: 10.1073/pnas.1116510109 22431598
33. Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, Waterson AG, Lee T, Rossanese OW, Fesik SW, Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl 2012;51:6140–6143. doi: 10.1002/anie.201201358 22566140
34. Shima F, Yoshikawa Y, Ye M, Araki M, Matsumoto S, Liao J, Hu L, Sugimoto T, Ijiri Y, Takeda A, Nishiyama Y, Sato C, Muraoka S, Tamura A, Osoda T, Tsuda K.-I, Miyakawa T, Fukunishi H, Shimada J, Kumasaka T, Yamamoto M, Kataoka T, In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras–effector interaction. Proc Natl Acad Sci U S A 2013;110:8182–8187. doi: 10.1073/pnas.1217730110 23630290
35. Rosnizeck IC, Graf T, Spoerner M, Tränkle J, Filchtinski D, Herrmann C, Gremer L, Vetter IR, Wittinghofer A, König B, Kalbitzer HR, Stabilizing a Weak Binding State for Effectors in the Human Ras Protein by Cyclen Complexes. Angew Chem Int Ed Engl 2010;49:3830–3833. doi: 10.1002/anie.200907002 20401883
36. Rosnizeck IC, Spoerner M, Harsch T, Kreitner S, Filchtinski D, Herrmann C, Engel D, König B, Kalbitzer HR, Metal–Bis(2-picolyl)amine Complexes as State 1(T) Inhibitors of Activated Ras Protein. Angew Chem Int Ed Engl 2012;51:10647–10651. doi: 10.1002/anie.201204148 22996816
37. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM, K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013;503:548–551. doi: 10.1038/nature12796 24256730
38. Hocker HJ, Cho KJ, Chen CY, Rambahal N, Sagineedu SR, Sharri K, Stanslas J, Hancock JF, Gorfe AA, Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function. Proc Natl Acad Sci U S A 2013; 110:10201–10206. doi: 10.1073/pnas.1300016110 23737504
39. Omerovic J, Prior IA, Compartmentalized signalling: Ras proteins and signalling nanoclusters. FEBS J 2009;276: 1817–1825. doi: 10.1111/j.1742-4658.2009.06928.x 19243428
40. Prior IA, Hancock JF, Compartmentalization of Ras proteins. J Cell Sci 2001;114: 1603–1608. 11309191
41. Hancock JF, Prior IA, Electron microscopic imaging of Ras signaling domains. Methods 2005;37: 165–172. 16288888
42. Aran V, Prior IA, Compartmentalized Ras signaling differentially contributes to phenotypic outputs. Cell Signal 2013;25: 1748–1753. doi: 10.1016/j.cellsig.2013.05.004 23707528
43. Gorfe AA, Grant BJ, McCammon JA, Mapping the nucleotide and isoform-dependent structural and dynamical features of Ras proteins. Structure 2008;16: 885–896. doi: 10.1016/j.str.2008.03.009 18547521
44. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53: 549–554. 2453289
45. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321: 1801–1806. doi: 10.1126/science.1164368 18772397
46. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M, Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987;327: 298–303. 2438556
47. Riely GJ, Marks J, Pao W, KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009;6: 201–205. doi: 10.1513/pats.200809-107LC 19349489
48. van 't Veer LJ, Burgering BM, Versteeg R, Boot AJ, Ruiter DJ, et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989;9: 3114–3116. 2674680
49. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, et al. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994;102: 285–290. 8120410
50. Luo D, Liu QF, Gove C, Naomov N, Su JJ, et al. Analysis of N-ras gene mutation and p53 gene expression in human hepatocellular carcinomas. World J Gastroenterol 1998; 4: 97–99. 11819246
51. Burchill SA, Neal DE, Lunec J, Frequency of H-ras mutations in human bladder cancer detected by direct sequencing. Br J Urol 1994;73: 516–521. 8012773
52. Castro P, Soares P, Gusmao L, Seruca R, Sobrinho-Simoes M, H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid. Oncogene 2006;25: 4620–4627. 16532025
53. Marcus K, Mattos C, Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects. Clin Cancer Res 2015;21: 1810–1818. doi: 10.1158/1078-0432.CCR-14-2148 25878362
54. Gorfe AA, Hanzal-Bayer M, Abankwa D, Hancock JF, McCammon JA, Structure and dynamics of the full-length lipid-modified H-Ras protein in a 1,2-dimyristoylglycero-3-phosphocholine bilayer. J Med Chem 2007;50: 674–684. 17263520
55. Abankwa D, Hanzal-Bayer M, Ariotti N, Plowman SJ, Gorfe AA, et al. A novel switch region regulates H-ras membrane orientation and signal output. EMBO J 2008;27: 727–735. doi: 10.1038/emboj.2008.10 18273062
56. Abankwa D, Gorfe AA, Inder K, Hancock JF, Ras membrane orientation and nanodomain localization generate isoform diversity. Proc Natl Acad Sci U S A 2010;107: 1130–1135. doi: 10.1073/pnas.0903907107 20080631
57. Abankwa D, Gorfe AA, Hancock JF, Ras nanoclusters: molecular structure and assembly. Semin Cell Dev Biol 2007;18: 599–607. 17897845
58. Janosi L, Gorfe AA, Segregation of negatively charged phospholipids by the polycationic and farnesylated membrane anchor of Kras. Biophys J 2010;99: 3666–3674 doi: 10.1016/j.bpj.2010.10.031 21112291
59. Darden T, York D, Pedersen L, Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. J Chem Phys 1993;98: 10089–10092.
60. Ryckaert JP, Ciccotti G, Berendsen HJC, Numerical integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes. J Comput Phys 1977;23: 327–341.
61. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. Scalable molecular dynamics with NAMD. J Comput Chem 2005; 26: 1781–1802. 16222654
62. MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FT, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WE, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiórkiewicz-Kuczera J, Yin D, Karplus M, All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins. J Phys Chem B 1998;102:586–3616.
63. Klauda JB, Venable RM, Freites JA, O'Connor JW, Tobias DJ, et al. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. J Phys Chem B 2010;114: 7830–7843. doi: 10.1021/jp101759q 20496934
64. Humphrey W, Dalke A, Schulten K, VMD: visual molecular dynamics. J Mol Graph 1996;14: 33–38. 8744570
65. Grossfield A, Zuckerman DM, Quantifying uncertainty and sampling quality in biomolecular simulations. Annu Rep Comput Chem 2009;5: 23–48. 20454547
66. Stephen AG, Esposito D, Bagni RK, McCormick F, Dragging ras back in the ring. Cancer Cell 2014;25: 272–281. doi: 10.1016/j.ccr.2014.02.017 24651010
67. Fenimore PW, Frauenfelder H, McMahon BH, Parak FG, Slaving: solvent fluctuations dominate protein dynamics and functions. Proc Natl Acad Sci U S A 2002;99: 16047–16051. 12444262
68. Prakash P, Sayyed-Ahmad A, Gorfe AA, The role of conserved waters in conformational transitions of Q61H K-ras. PLoS Comput Biol 2012;8: e1002394. doi: 10.1371/journal.pcbi.1002394 22359497
69. Buhrman G, O′Connor C, Zerbe B, Kearney BM, Napoleon R, et al. Analysis of Binding Site Hot Spots on the Surface of Ras GTPase. J Mol Biol 2011;413: 773–789. doi: 10.1016/j.jmb.2011.09.011 21945529
70. Grant BJ, Lukman S, Hocker HJ, Sayyah J, Brown JH, et al. Novel allosteric sites on Ras for lead generation. PLoS One 2011;6: e25711. doi: 10.1371/journal.pone.0025711 22046245
71. Halgren TA, Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 2009;49: 377–389. doi: 10.1021/ci800324m 19434839
72. Schmidtke P, Bidon-Chanal A, Luque FJ, Barril X, MDpocket: open-source cavity detection and characterization on molecular dynamics trajectories. Bioinformatics 2011;27: 3276–3285. doi: 10.1093/bioinformatics/btr550 21967761
73. Durrant JD, Lindert S, McCammon JA, AutoGrow 3.0: an improved algorithm for chemically tractable, semi-automated protein inhibitor design. J Mol Graph Model 2013;44: 104–112. doi: 10.1016/j.jmgm.2013.05.006 23792207
74. Smith MJ, Neel BG, Ikura M, NMR-based functional profiling of RASopathies and oncogenic RAS mutations. Proc Natl Acad Sci U S A 2013;110: 4574–4579. doi: 10.1073/pnas.1218173110 23487764